Objective To compare the efficacy and safety of IL-23 p19 monoclonal antibodies for moderate-to-severe plaque psoriasis. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 21 February 2026. We included randomized controlled trials of guselkumab, risankizumab, tildrakizumab,...